Endocrine side effects during cancer treatment. Lecture for practitioners

Anastasiya A. Glibka; Глибка Анастасия Андреевна; Natalya V. Mazurina; Мазурина Наталия Валентиновна; Ekaterina A. Troshina; Трошина Екатерина Анатольевна

doi:10.26442/20751753.2022.6.201695

Endocrine side effects during cancer treatment. Lecture for practitioners

Authors: Glibka A.A.¹, Mazurina N.V.¹, Troshina E.A.¹
Affiliations:
1. Endocrinology Research Centre
Issue: Vol 24, No 6 (2022)
Pages: 416-421
Section: Articles
URL: https://journals.rcsi.science/2075-1753/article/view/109885
DOI: https://doi.org/10.26442/20751753.2022.6.201695
ID: 109885

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Targeted therapy and immune checkpoint inhibitors (ICI) are increasingly being used to treat many solid tumors. The use alpelisib and ICPI has a risk of side-effects, particularly endocrine dysfunctions. In this lecture, there are clearly stated: initial screening, monitoring, selection of therapy and emergency situations for each endocrinopathy, i.e. hyperglycemia during treatment with alpelisib and destructive thyroiditis and hypophysitis during treatment of ICI.